A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations
H Deng, Q Lei, C Wang, Z Wang, H Chen… - Nature …, 2022 - nature.com
Therapeutic responses of non-small cell lung cancer (NSCLC) to epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR …
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR …
The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer
J Zhao, X Wang, L Xue, N Xu, X Ye, H Zeng… - Journal of cancer …, 2014 - Springer
Purpose We aimed to quantify the epidermal growth factor receptor (EGFR) mutation in
tumors and to analyze its prediction of EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment …
tumors and to analyze its prediction of EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment …
[HTML][HTML] Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision
AC Sousa, C Silveira, A Janeiro, S Malveiro… - Lung Cancer, 2020 - Elsevier
Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are
biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR …
biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR …
Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non–small-cell lung cancer
T Ikeda, Y Nakamura, H Yamaguchi, N Tomonaga… - Clinical Lung Cancer, 2012 - Elsevier
Background Epidermal growth factor receptor (EGFR) mutations are predictive of response
to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Several methods have been used to …
to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Several methods have been used to …
Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on exon classification, and structure …
R Kitadai, Y Okuma - Cancers, 2022 - mdpi.com
Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
IJ Dahabreh, H Linardou, F Siannis, P Kosmidis… - Clinical Cancer …, 2010 - AACR
Purpose: The aim of this systematic review and meta-analysis was to characterize common
EGFR molecular aberrations as potential predictive biomarkers for response to monotherapy …
EGFR molecular aberrations as potential predictive biomarkers for response to monotherapy …
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy
RK Kancha, N Von Bubnoff, C Peschel, J Duyster - Clinical cancer research, 2009 - AACR
Purpose: Epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer
(NSCLC) might be predictive for clinical response to EGFR inhibitor treatment. However …
(NSCLC) might be predictive for clinical response to EGFR inhibitor treatment. However …
Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR‑TKIs in advanced non‑small‑cell lung cancer
Y Wang, J Duan, H Chen, H Bai, T An… - Oncology …, 2017 - spandidos-publications.com
The detection of mutations in the epidermal growth factor receptor (EGFR) gene in tumor
tissues has been established as the gold standard for predicting the efficacy of treatment …
tissues has been established as the gold standard for predicting the efficacy of treatment …
Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung …
HS Kim, JS Sung, SJ Yang, NJ Kwon, LH Jin, ST Kim… - PloS one, 2013 - journals.plos.org
Direct sequencing remains the most widely used method for the detection of epidermal
growth factor receptor (EGFR) mutations in lung cancer; however, its relatively low sensitivity …
growth factor receptor (EGFR) mutations in lung cancer; however, its relatively low sensitivity …
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction
SG Wu, YL Chang, JW Lin, CT Wu, HY Chen, MF Tsai… - PloS one, 2011 - journals.plos.org
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small
cell lung cancer, especially adenocarcinoma. Tumors with EGFR mutations showed good …
cell lung cancer, especially adenocarcinoma. Tumors with EGFR mutations showed good …
相关搜索
- lung cancer egfr tkis
- fluorogenic probe treatment response
- lung cancer tissue and plasma
- lung cancer direct comparison
- nsclc patients egfr mutations
- tissue and plasma egfr tkis
- lung carcinoma egfr mutation
- predictive efficacy egfr mutation
- treatment decision egfr mutations
- drug sensitivity egfr mutations
- direct comparison egfr mutations
- functional analysis egfr mutations
- treatment decision nsclc patients
- lung cancer egfr mutations
- treatment strategies egfr mutations
- predictive biomarkers egfr mutation